Pfizer Inc. (NYSE:PFE) is included among the 13 Best Dividend Stocks Paying Over 6%. UBS Likes Pfizer’s MTSR Obesity Deal but Stays Neutral on PFE On January 7, UBS initiated coverage of Pfizer Inc. (NYSE:PFE) with a Neutral rating and a $25 price target. The firm pointed to lingering uncertainty around Pfizer’s revenue outlook, with roughly$15 billion to $20 billion tied to major drugs expected to lose patient exclusivity over the next three years. UBS said it likes the recent MTSR obesity deal, but ad ...